ABSTRACT
Objective: The objective of the study was to evaluate the clinical efficacy of kanglaite (KLT) injection combined with gefitinib versus gefitinib alone in the treatment of nonsmall cell lung cancer (NSCLC). Methods: The randomized controlled trials involving NSCLC treatment with KLT injection combined with gefitinib versus gefitinib alone were searched on seven medical databases up to October 2016. Two reviewers independently assessed the methodological quality of the included studies. The RevMan 5.3 software was employed for data analysis. Results: Seven randomized trials involving 554 patients met our criteria. Compared with gefitinib alone, KLT injection combined with gefitinib showed significant effects in increasing objective response rate (relative risk [RR] =1.38; 95% confidence interval [CI], 1.09–1.75), improving the performance status (RR = 1.80; 95% CI: 1.34–2.42), raising the percentages of CD4+ cells (weighted mean difference [WMD] = 4.45; 95% CI: 2.61–6.28), natural killer cells (WMD = 4.43; 95% CI: 3.85–5.01), and ratio of CD4+/CD8+ (WMD = 0.08; 95% CI: 0.02–0.14), whereas the difference was not significant in gefitinib toxicity including rash (RR 0.90; 95% CI: 0.58–1.40, P = 0.65), diarrhea (RR 1.04; 95% CI: 0.66–1.64, P = 0.88), and liver injury (RR 1.00; 95% CI: 0.58–1.73, P = 1.00), CD3+ cells (WMD = 1.16; 95% CI: -2.64–4.97) and CD8+ cells (WMD = 6.78; 95% CI: -1.68–15.23). Conclusion: Co-use of KLT injection and gefitinib may benefit the patients with NSCLC through enhancing the therapeutic effectiveness compared with gefitinib alone. To confirm these results, further rigorously designed trials are warranted
ABSTRACT
Objective To investigate the effect of Kanglaite injection combined with NP (navelbine +cisplatin)chemotherapy for immune status,inflammatory factors and quality of life of patients with advanced non-small cell lung cancer (NSCLC). Methods A total of 106 patients with advanced NSCLC admitted to our hospital from June 2014 to January 2017 were divided into control group and observation group according to ad-mission even and odd numbers,and 53 cases in each group. The patients in control group received chemothera-py with NP regimen,and the patients in observation group received Kanglaite injection + NP regimen chemo-therapy. The immune status,inflammatory factors and quality of life of the patients in the two groups were ob-served and compared statistically. Results After treatment,the immune indexes including CD3 +(62. 64％ ± 3. 96％ vs. 54. 08％ ± 7. 19％),CD4 +(37. 10％ ± 5. 09％ vs. 29. 22％ ± 6. 38％),CD4 + / CD8 +(1. 96 ± 0. 62 vs. 1. 12 ± 0. 39)and natural kill cells (22. 45％ ± 5. 92％ vs. 16. 37％ ± 6. 13％)of observation group were apparently higher than those of control group (t = 7. 592,P < 0. 001;t = 7. 029,P < 0. 001;t = 8. 349, P < 0. 001;t = 5. 194,P < 0. 001). After treatment,the levels of interleukin-6 [(80. 56 ± 10. 27)ng/ L vs. (102. 87 ± 14. 58)ng/ L],tumor necrosis factor-α [(8. 35 ± 2. 73)ng/ L vs. (15. 69 ± 3. 14)ng/ L],C-re-active protein [(9. 18 ± 2. 38)mg/ L vs. (13. 84 ± 2. 92)mg/ L]of observation group were significantly lower than those of control group (t = 9. 107,P < 0. 001;t = 12. 843,P < 0. 001;t = 9. 006,P < 0. 001). The im-proved condition of Karnofsky performance status score of observation group was significantly better than that of control group (Z = 3. 133,P = 0. 002). The effective rate of observation group was significantly higher than that of control group (58. 49％ vs. 35. 85％),with significant difference (χ2 = 5. 451,P = 0. 020). Conclu-sion The efficacy of Kanglaite injection combined with NP regimen in the treatment of advanced NSCLC is positive,which can effectively improve the immune status of patients,reduce inflammatory reaction and improve quality of life.
ABSTRACT
OBJECTIVE:To systematically review the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of the non-small cell lung cancer (NSCLC),and provide evidence-based reference for clinical treatment. METH-ODS:Retrieved from PubMed,Cochrane Library,EMBase,VIP,CJFD,Wanfang database and CBM,randomized controlled tri-als(RCT)about the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC were collect-ed. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with modified Jadad scale. RESULTS:Totally 9 RCTs were included,involving 561 patients. Results of Meta-analysis showed,Kanglaite injection com-bined with radiothreapy can significantly improve the effective rate [OR=2.99,95%CI(2.07,4.31),P<0.001] and improvement rate of life quality [OR=3.74,95%CI(2.36,5.92),P<0.001],and reduce the incidence of radiation pneumonitis [OR=0.23,95%CI (0.12,0.47),P<0.001] and radiation esophagitis [OR=0.10,95%CI(0.05,0.21),P<0.001] of NSCLC patients,the differences were statistically significant. CONCLUSIONS:Both the efficacy and safety of Kanglaite injection combined with radiothreapy in the treatment of NSCLC are superior to radiothreapy alone.
ABSTRACT
Objective To study effects of Kanglaite injection combined with gefitinib on inflammatory factors and immune function in patients with advanced lung cancer.Methods 98 patients with advanced lung cancer in First People 's Hospital of Yuhang District from December 2013 to September 2016 were selected and randomly divided into gefitinib-treated group and combination drug-treated group with 49 cases in each group.The patients in the gefitinib-treated group were treated with gefitinib, the patients in the combination drug-treated group were treated with gefitinib and Kanglaite injection.The clinical efficacy, inflammatory factors, immune function, quality of life and adverse reactions were observed and compared between the two groups. Results The efficacy and control rate in combination drug-treated group were higher than gefitinib-treated group(P<0.05).The inflammatory factors such as CRP, IL-6 and TNF-αwere significantly improved in the two groups before treatment, and the combination drug-treated group improved significantly better than gefitinib-treated group(P<0.05).The levels of cellular immune factors in the two groups were significantly improved compared with that before treatment, and the combination drug-treated group was significantly better than the gefitinib-treated group(P<0.05).The quality of life in the combination drug-treated group was significantly higher than the gefitinib-treated group(P<0.05).The incidence of adverse reactions such as nausea and vomiting, thrombocytopenia, and renal dysfunction in combination drug-treated group was lower than in the gefitinib-treated group( P<0.05).Conclusion Application of gefitinib combined with Kanglaite injection in the treatment of patients with advanced lung cancer treatment is more significant, can effectively reduce the systemic inflammation and adverse reactions, improve immune function and quality of life.
ABSTRACT
Objective To investigate the clinical curative effect and security of Kanglaite injection in combination with low power ultrasound microbubble agents (cavitation) in the treatment of vascular embolization therapy.Methods Thirty-eight patients with abdominal malignant tumor,in accordance with the random number table,were divided into two groups:treatment group (Kanglaite combined with ultrasonic cavitation,21 cases) and control group (Kanglaite,17 cases).Intravenous drip with Kanglaite injection for 21 days,200 ml per day.Ultrasonic cavitation therapy treatment for three weeks,5 days a week and once a day.Tumors size,Karnofsky score,grade of the degree of pain and blood biochemical indicator detection were measyred before and after treatment.Results There was no complete remission,4 cases with partial remission,10 cases with stable disease in the treatment group,and the clinical benefit rate was 66.7％ (14/21).There was no complete remission,1 case with partial remission,3 cases with stable diseasein in control group,and the clinical benefit rate was 23.5％ (4/17).The treatment group was better than control group in clinical benefit rate (66.7％ ∶ 23.5％),pain improvement (76.2％ ∶ 41.2％),Karnofsky score [(66.67 ± 5.77) ∶ (82.86 ± 6.44);(64.12 ±5.07) ∶ (69.41 ±6.59)],and one year survival rate (57.1％ ∶23.5％) (x2 =7.012,P =0.008;x2 =4.821,P=0.028;t=4.575,P＜0.001;x2 =4.354,P=0.037).Conclusion Kanglaite injection in combination with cavitation shows higher clinical efficient,tolerated adverse recations,and significant improvement of quality of life.
ABSTRACT
Objective To investigate effects of Kanglaite injection on proliferation, cycle and apoptosis of human breast cancer MCF-7 cells;To discuss its relevant mechanism. Methods Logarithmic growth phase cells were divided into control group and Kanglaite-treatment group (10, 20, 40μL/mL). Cells were cultured in RPMI-1640 for 24 h before drug treatment. The inhibition rate of Kanglaite injection on proliferation of human breast cancer MCF-7 cells was detected by MTT assay. Apoptosis and cell cycle of MCF-7 cells were detected by flow cytometry. Changes in cell nucleus were determined by Hochest staining assay. Protein expressions of Bcl-2 and Bax were detected by ELISA and Western blot. Results Kanglaite injection for 12 h, 24 h or 48 h resulted in a significant inhibition of MCF-7 cells proliferation (P<0.05, P<0.01);Compared with the control group, Kanglaite injection-treated cells showed increased percentage in G2/M and G0/G1 phases (P<0.001, P<0.01), but showed decreased percentage in S phase (P<0.01), and apoptosis rate increased (P<0.05, P<0.001). Kanglaite injection significantly decreased protein expression of Bcl-2, and enhanced protein expression of Bax of MCF-7 cells (P<0.01, P<0.001). Conclusion Kanglaite injection can inhibit the proliferation of human breast cancer MCF-7 cells, decrease cell cycle and induce apoptosis, the mechanism is related with decreasing protein expression of Bcl-2 and enhance the protein expression of Bax.
ABSTRACT
Objective To study the effect of Kanglaite combined with comprehensive therapy on advanced non-small cell lung cancer.Methods Sixty-one patients with advanced non-small cell lung cancer were randomly divided into treatment group ( n=31 ) and control group ( n=30 ).Both groups were given comprehensive therapy.Treatment group were additionally treated with intravenous injection of 200 ml Kanglaite.Clinical efficacy,quality of life,pain relief and adverse reactions of the two groups were observed.Results ( 1 ) Quality of life was improved in 20 cases (64.5％ ),stabled in 8 cases (25.8％),declined in 3 cases ( 9.7％ ) of treatment group,and in the control group there were 9 cases ( 30.0％ ) improved,9 cases ( 30.0％ ) stabilized,12 cases (40.0％ ) declined respectively.Quality of life in treatment group was higher than in control group ( U=2.91,P＜0.01 ).( 2 ) Pain relief:the number of patients with complete remission,partial remission,no change,and progression were 5 cases ( 16.1％ ),16 cases ( 51.6 ％ ),16 cases (51.6％ ),6 cases (19.4％) and 4 cases (12.9％ ) in treatment group,and in control group they were 2 cases(6.7％ ),9 cases (30.0％ ),11 cases(36.7％ ) and 8 cases(26.7％ ) respectively.The effect of treatment on pain relief in treatment group was better than that in control group ( U=2.32,P＜0.05 ).(3) Clinical efficacy:in the treatment group there were 12 cases (38.7％) with partial remission,14 cases (45.2％) stabilized,and 5 cases (16.1％ ) progressed,and in control group the numbers were 8 cases (26.7％ ),8 cases (26.7％ ) and 14 cases (46.7％ ) respectively.The clinical efficacy in treatment group was better than that in the control group( U=2.04,P＜0.05).(4) There were significant difference on the change of white blood cell count and gastrointestinal reactions Ⅲ and Ⅳ degrees between treatment group and contrl group [22.6％ (7/31) vs.53.3％(16/30),x2=6.139 P＜0.05;19.4％ (6/31) vs.46.7％ (14/30),x2=5.161,P＜0.05].Conclusion Kanglaite injection combined with comprehensive therapy can improve clinical efficacy of therapy for advanced non-small cell lung cancer,reduce the toxic adverse reaction,protect immunity system and improve the quality of life of patients.
ABSTRACT
Objective To investigate the effect of Kanglaite injection (KLT) on immunological function of rat models with Lewis lung carcinoma. Methods Forty C57BL/6 mice were used to establish Lewis lung carcinoma models and divided randomly into the high dose(25 mL/kg), middle dose (12.5 mL/kg) and low dose (6.25 mL/kg) of KLT groups and model group(n=10). The mice in the KLT groups were sacrificed after injecting corresponding dose of KLT with intraperitoneal injection for 14 d. No treatment was performed on the rats in model group. The body weight, tumor and spleen weight was weighed, then the ratio of tumor restriction and the index of spleen was calculated. MTT colorimetric method and ELISA were used to detected activity of T cell proliferation and expression of IL-2 in spleen. The expression of NF-κB and IκBα protein was detected by Western blot. Results The ratio of tumor restriction in the high, middle, low dose of KLT groups decreased gradually. The indexes of spleen of the high and middle dose of KLT groups were higher than those in the model group (P<0.05 or P<0.01).Compared with the model group, the activity of T cell proliferation in the high, middle, low dose of KLT groups and the expression of IL-2 in the high and middle dose of KLT groups was increased significantly (P<0.05 or P<0.01). The expression of NF-κB protein in the nuclei of high, middle, low dose of KLT groups increased dose-dependently, and the expression of NF-κB and IκBα protein in the cytoplasm decreased dose-dependently. ConclusionKLT could enhance immunological function by effecting T cell proliferation, expression of IL-2, NF-κB and IκBα, while restricting tumor growth in Lewis lung carcinoma models.
ABSTRACT
Objective To investigate the anti-tumor effects of a combination of Kanglaite injection (KI) and photodynamic therapy (PDT) on human pancreatic cancer SW1990 xenograft in nude mice.Methods The animal model of human pancreatic cancer was developed by suturing small pieces of SW1990 tumors into the dorsum of nude mice.60 rats were randomly divided into six groups:group A ( control group without treatment),group B ( receiving 1.25g/kg KI via the tail vein prior to PDT and continuously for 10 days),group C (receiving 2.5g/kg KI via the tail vein continuously for 10 days),group D (PDT group,2 mg/kg Photosan 48h prior to laser irradiation),group E ( group B + group D),group F ( group C + group D)with 10 rats in each group.The tumor sizes were measured twice per week.The mice were sacrificed on the 14th day of PDT treatment.The tumor was took out and weighted and the tumor inhibitory rate was analyzed.Results The tumor volumes of group A to F were 9550.08±52.46)mm3,(519.71±46.44)mm3,(405.29±38.67 ) mm3,( 199.27±37.37) mm3,( 107.47±14.13 ) mm3 and (75.58±12.53 )mm3,the weight of group A to F were (0.82±0.08)g,(0.77±0.06)g,(0.61±0.06)g,(0.41±0.05)g,(0.28±0.04)gand (0.16±0.04)g,respectively.The tumor volumes and tumor weights of the two combined groups were significandy smaller than those in the other groups (P＜0.05).The combination group of 1.25 g/kg KI increased the tumor inhibitory rate from 50% in PDT group to 65.9%.The combination group of 2.5 g,/kg KI increased the tumor inhibitory rate to 80.5%.Conclusions KI had attenuated effect on PDT therapy,and the combination of KI and PDT could significantly inhibit the tumor growth.
ABSTRACT
Objective To study and evaluate the effects of Kanglaite Injection (KLT) in rat model of cancer pain. Methods According to Medhurst' method, a rat model of cancer-induced bone pain wasestablished by intra-tibial injection of 3?103 MRMT-1 rat mammary gland carcinomal cells in Sprague-Dawley rats. KLT group were treated with 10 mL/kg of KLT, ip, twice daily from day 8 to day 17 after injection of MRMT-1 cells. In celecoxib group, 30 mg/kg, ig, twice daily for 10 days. NS group and sham group were given with 10 mL/kg of NS, ip, twice daily for 10 days. On day 17, rats in morphine group received a single administration of 3 mg/kg morphine. Pain-related behaviors including allodynia (the hind paw withdrawal response to 2 g von Frey filament stimulation) and the difference of weight bearing between hind paws were measured in all 5 groups on day 17. In addition, the left hind limbs were removed and X-rays were obtained for assessing of tumor-induced bone destruction. Results On day 17 after injection of MRMT-1 cells or NS, the paw withdrawal response frequency to 2 g von Frey filament stimulation on the left paw in KLT group, celecoxib group, morphine group and NS group were 53.3%?20.7%, 46.7%?20.7%, 13.3%?16.3% and 90% ?16.7%, respectively. The paw withdrawal response frequency in KLT group was significantly decreased compared with that in NS group (P
ABSTRACT
0.05). The improvement rate evaluated by karnofsky score was 64.7% in the treatment group and 41.2% in the control group,the difference being significant (P
ABSTRACT
Objective To investigte the inhibit effects of drug combination of Kanglaite injection(KLT) and TXT on human pulmonary epithelial cells(95D) in vitro,and to find the best time of combination.Method 95D cell growth inhibition was measured with MTT assay.Results Various concentration of KLT and TXT could inhibit the proliferation of 95D cell,and KLT could enchance the sensiti vity of 95D cell to TXT(P
ABSTRACT
AIM:To research the effects of Kanglaite(KLT)injection on antitumor and expression of epidermal growth factor receptor(EGFR)in Lewis lung carcinoma(LLC).METHODS:A total of 40 C57BL/6 mice were randomly divided into four groups,including model group,KLT 6.25,12.5,25 mL/kg groups.All the mice were injected with 2?106 LLC cells at 1st day.At the next day,mice in the KLT groups were peritoneally injected with KLT for 14 days.And at the 16th day,all the mice were sacrificed and the tumors were harvested.The tumor weight was measured and the tumor growth inhibition rate was analyzed.The expression of EGFR was detected by westernblot.RESULTS:The growth of LLC was significantly inhibited by KLT,the changes of tumor appearance and histology were affected and the expression level of EGFR was decreased.CONCLUSION:KLT injection could obviously inhibit the growth of LLC,whose mechanism maybe related to the inhibition of EGFR expression.
ABSTRACT
Objective:A combined therapy of Aidi and Kanglaite injection was employed to enhance the living quality of patients with tumors.Method: 50ml Aidi was added into 5% glucose 500ml,together with100 to 200 ml Kanglaite was injected per day,a medical treatment course lasts for 15 to 20 days,and the duration includes 1 to 3 courses.Result: 25% of all patients treated show a complete cure of tumor pain,43.8% of all patients show relief to some extent,with a total efficiency of 68.8%,and 72.8% of all treatment group show an increase in living quality.Conclusion: The combined therapy together with humanistic nursing care results in a significant effect in treating patients with terminal tumors.
ABSTRACT
Objective To observe the preventive and therapeutic effect of Ka ng laite Injection (KI) on acute nephrotoxicity in rats induced by cisplatin (DDP) and gemzar.Methods Forty SD rats, male and female in a half, were randomized in to normal control group, KI group, DDP+ Gemzar group and KI+ DDP+ Gemzar gro up, 5 male and 5 female in each group. The KI+ DDP+ Gemzar group were given K I 10 mL/kg first,DDP injection 6 mg/kg 2 hours later and Gemzar injection 90 mg/ kg 4 hours later. After treatment, acute nephrotoxicity was observed.Results On e week after treatment, all of the rats survived; the body weight of the male an d female rats in group was similar in KI group and in the normal control group, but lower in DDP+ Gemzar group, in particular the male rats, than that in norma l control group. Body weight in KI+ DDP+ Gemzar group was lower than that in the normal control group but higher than that in DDP+ Gemzar group.The serum le vels of biochemical parameters were similar in KI group and the normal control g roup; serum levels of total protein (TP) and albumin(ALB) were markedly lower bu t those of blood urea nitrogen (BUN) and creatine (CRE) higher in DDP+ Gemzar g roup than those in the normal control group; the above indexes were improved in KI+ DDP+ Gemzar group as compared with those in DDP+ Gemzar group and arrive to the normal level.Conclusion KI has preventive and therapeutic effect on acu te nephrotoxicity in rats induced by DDP and Gemzar.
ABSTRACT
Objective To observe the attenuated effect of Kanglaite Injecti on (KI) combined with chemotherapeutic drugs on transplanted human lung cancer A54 9 in nude mice. Methods Ninety- six nude mice were transplanted subcutaneousl y with human lung cancer A549; 7 days later, the mice were randomized into 16 gr oups(n=6) and were given antitumor drugs according the regimen. Other 12 normal mice were used as controls. KI groups were given KI 1.25, 2.5 and 5.0 g/kg respe ctively and were administered (iv) continuously for 10 times on 7th day of trans plantation; cisplatin (DDP, 1.5 mg/mg or 3 mg/kg) and Gemzar (30 mg/kg or 60 mg/ kg) were given one dose by intraperitoneal injection on 10th day of transplantat ion; Gemzar was given again 4h after medication of DDP. Taxotere (25 mg/kg) was given one dose by intraperitoneal injection on 7th day of transplantation. The m ice were killed to examine the body weight, tumor weight and tumor- inhibiting rate. Results KI 1.25, 2.5 and 5.0 g/kg respectively combined with DDP 3mg/kg and Gemzar 60 mg/kg had a better inhibitory effect on the growth of human lung c ancer A549 than KI, DDP and Gemzar alone. KI in three doses respectively combine d with DDP 1.5 mg/kg and Gemzar 30 mg/kg not only had a better inhibitory effect than those of KI, DDP and Gemzar alone, but also promoted the antitumor actions . The tumor- inhibitory rate of KI in three doses respectively combined with Ta xotere (25 mg/kg) was higher than KI and Taxotere alone. Conclusion KI combine d with DDP and Gemzar or with Taxotere can shorten the tumor mass and has tumor - inhibitory and attenuated effect.
ABSTRACT
0.05). However,life quality was improved and the improvement of clinical symptoms was more obviously in the treatment group as compared with the control group.Conclusion KI combined with chemotherapy and radiotherapy could increase the effects,improve and decrease the side effects.
ABSTRACT
OBJECTIVE:To observe the clinical therapeutic effect of KLT combined with chemotherapy on late can?cers.METHODS:64patients with late cancers were assigned as observation group:receiving KLT+chemotherapy;47patients with late cancers were assigned as control group:receiving routine chemotherapy.RESULTS:In the observation group,the ef?fective rate was48.44%,body weight increase accounted for57.81%,KSP increased85.93%and relief from pain accounted for71.87%;In the control group:the effective rate was34.04%,body weight increase accounted for22.66%,KSD increased48.93%and relief from pain accounted for46.81%.The incidence of ARDs in observation group was obviouly lower than those in control group.CONCLUSION:KLT combined with chemotherapy can raise the therapeut effect on patients with late cancers and improve their life quality.